Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Little evidence is available on circulating phosphatidylinositol and phosphatidylserine, which have been found to be higher in MASL(101, 102) or only in MASH (phosphatidylinositol).108”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“High levels of plasma ceramides are correlated with the severity of MASLD and reflect hepatic ceramide accumulation.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Plasma saturated/unsaturated fatty acid TAGs have been found to be elevated,102,103 and associated with IR11,104 in individuals with MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“Patients with MASH have 20% higher ceramide concentrations compared to healthy individuals.100,102,104,117”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
In the citing paper
“A few studies have also investigated circulating lipidomic species in patients with advanced forms of MASH (F3), fibrosis, and cirrhosis, showing an increase in circulating levels of some ceramides (d18:1/20:0, d18:1/22:0, d18:1/23:0, d18:1/24:1, d18:1/24:0) and a decrease in hexosylceramide,115 some glucosylceramide (d18:1/24:1, d18:1/26:1, 18:1/26:0), SM, PC, LPC, and phosphatidylinositol94,102”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [102]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Self-citation
Cited by
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W.-S., Adams, L. A., de Lédinghen, V., Wong, G. L.-H., & Sookoian, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 614
Pierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Seidman, J. S., Troutman, T. D., Sakai, M., Gola, A., Spann, N. J., Bennett, H., Bruni, C. M., Ouyang, Z., Li, R. Z., Sun, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.001 · Cited by 443
“A corresponding increase in desmosterol was reported in livers of human subjects with NASH and cirrhosis (Gorden et al., 2015).”
BackgroundSelf-citationMetabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Bowden, J. A., Heckert, A., Ulmer, C. Z., Jones, C. M., Koelmel, J. P., Abdullah, L., Ahonen, L., Alnouti, Y., Armando, A. M., Asara, J. M., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m079012 · Cited by 403
Self-citationDistinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
“IVA337, a pan-agonist that prevents and reverses skin fibrosis (183), is currently entering phase 2 trials for the treatment of NASH.”
InfluentialAn Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Burla, B., Arita, M., Arita, M., Bendt, A. K., Cazenave-Gassiot, A., Dennis, E. A., Ekroos, K., Han, X., Ikeda, K., Liebisch, G., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.s087163 · Cited by 312
Self-citationLipid alterations in chronic liver disease and liver cancer
Paul, B., Lewinska, M., & Andersen, J. B. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100479 · Cited by 308
“274 Interestingly, the FXR agonist obeticholic acid has shown promise as a therapeutic target in both NAFLD271 and PSC.272 Another noteworthy pathway is the cholesterol biosynthesis pathway; statins, which suppress HMGCR, have been studied in both NAFLD and PSC (Table S1) and successfully lowered LDL cholesterol in NA…”
BackgroundInfluentialDietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis
Hirsova, P., Ibrabim, S. H., Gores, G. J., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066357 · Cited by 270
“Finally, inhibition of hedgehog signaling by pharmacological inhibitors of smooth ened (vismodegib and erismodegib) or genetic deletion of smoothened in the liver parenchyma prevents liver injury, inflammation, and fibrosis in mouse models of NAFLD and NASH (51, 124).”
InfluentialLipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati-Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 249
Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy
Gantner, M. L., Eade, K., Wallace, M., Handzlik, M. K., Fallon, R., Trombley, J., Bonelli, R., Giles, S., Harkins-Perry, S., Heeren, T. F. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815111 · Cited by 243
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Mashek, D. G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101115 · Cited by 232
“In support, several metabolomic studies identified ceramides and other sphingolipids as predictive markers for the transition from steatosis to NASH [114,115].”
BackgroundMetabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 221
Jin, R., McConnell, R., Catherine, C., Xu, S., Walker, D. I., Stratakis, N., Jones, D. P., Miller, G. W., Peng, C., Conti, D. V., et al. (2020) · Environment International · doi:10.1016/j.envint.2019.105220 · Cited by 219
“For example, altered glycerophospholipids, such as increased phosphoethanolamine levels, were reported to be predictive biomarkers of NAFLD progression (Gorden et al., 2015).”
BackgroundPeng, K.-Y., Watt, M. J., Rensen, S., Greve, J. W., Huynh, K., Jayawardana, K. S., Meikle, P. J., & Meex, R. C. R. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m085613 · Cited by 220
Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
Hall, Z., Bond, N. J., Ashmore, T., Sanders, F., Ament, Z., Wang, X., Murray, A. J., Bellafante, E., Virtue, S., Vidal‐Puig, A., et al. (2017) · Hepatology · doi:10.1002/hep.28953 · Cited by 211
“Previous studies have concentrated on discovering biomarkers to differentiate between ‘healthy’ fatty liver (NAFL) and NASH (7-9), and to establish changes to the lipidome with progression of NAFLD (10, 11).”
BackgroundNeutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis
Sun, X., Seidman, J. S., Zhao, P., Troutman, T. D., Spann, N. J., Que, X., Zhou, F., Liao, Z., Pasillas, M., Yang, X., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.014 · Cited by 204
“Moreover, we analyzed plasma of subjects in whom liver status had been previously determined by liver biopsy (Gorden et al., 2015).”
MethodSelf-citationAn Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 204
“Sphingolipids, especially 1-deoxysphingolipids, were regarded as biomarkers of NAFLD progression in a recent omics approach [78].”
BackgroundFarrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Lipidomics unveils the complexity of the lipidome in metabolic diseases
Lydic, T. A., & Goo, Y. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0182-9 · Cited by 169
“Lipid profiling on plasma and liver of NAFLD patients identified 48 overlapping lipid species between liver and plasma [84].”
BackgroundPerakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 162
Recent advances in analytical strategies for mass spectrometry-based lipidomics
Xu, T., Hu, C., Xuan, Q., & Xu, G. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.09.060 · Cited by 160
Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
Xie, C., Yagai, T., Luo, Y., Liang, X., Chen, T., Wang, Q., Sun, D., Zhao, J., Ramakrishnan, S. K., Sun, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4412 · Cited by 161
Transforming Cancer Prevention through Precision Medicine and Immune-oncology
Kensler, T. W., Spira, A., Garber, J. E., Szabo, E., Lee, J. J., Dong, Z., Dannenberg, A. J., Hait, W. N., Blackburn, E., Davidson, N. E., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0406 · Cited by 154
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153
“Defining NAFL/NASH-associated lipid signatures for use in noninvasively benchmarking therapeutic responses will be invaluable (47).”
BackgroundAbulikemu, A., Zhao, X., Xu, H., Li, Y., Ma, R., Yao, Q., Wang, J., Sun, Z., Li, Y., & Guo, C. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102569 · Cited by 166
Ooi, G. J., Meikle, P. J., Huynh, K., Earnest, A., Roberts, S. K., Kemp, W., Parker, B. L., Brown, W., Burton, P., & Watt, M. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.013 · Cited by 137
Perakakis, N., Yazdani, A., Karniadakis, G. E., & Mantzoros, C. (2018) · Metabolism · doi:10.1016/j.metabol.2018.08.002 · Cited by 148
“Therefore, it is particularly important in diseases for which their pathogenesis is closely related to lipid metabolism, such as in obesity [42,43], T2D [44,45], atherosclerosis [46], hypertension [47], cardiovascular disease [48], stroke, metabolic syndrome [25] and nonalcoholic fatty liver disease [49].”
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 179
The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease
Song, M. J., & Malhi, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107401 · Cited by 155
Lipidomics in non-alcoholic fatty liver disease
Kartsoli, S., Kostara, C. E., Tsimihodimos, V., Bairaktari, E. T., & Christodoulou, D. K. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.436 · Cited by 163
Huang, J., Feng, S., Liu, A., Dai, Z., Wang, H., Reuhl, K. R., Lu, W., & Yang, C. S. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700696 · Cited by 146
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“In fact, PC and LPC, particularly PC(22:0, 20:4) and LPC(16:0,18:0), were found to be reduced in several studies, 107,109,110,112 while LPC (16:0, 16:1, 18:1, 20:0, 20:1) were increased in others 102,108,111,113 or increased in MASL and reduced in MASH.”
InfluentialLipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 148
“aqueous small molecular weight components involved in cellular metabolic pathways, facilitated differentiation between NASH and steatosis [122].”
Ruby, M. A., Massart, J., Hunerdosse, D. M., Schönke, M., Correia, J. C., Louie, S. M., Ruas, J. L., Näslund, E. B., Nomura, D. K., & Zierath, J. R. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.070 · Cited by 141
“The anti-inflammatory effects of CES2 overexpression suggest that decreased CES2 may promote the progression from NAFLD to non-alcoholic steatohepatitis (NASH).”
InfluentialO’Donnell, V. B., Dennis, E. A., Wakelam, M. J. O., & Subramaniam, S. (2019) · Science Signaling · doi:10.1126/scisignal.aaw2964 · Cited by 132
Self-citationSphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
Simón, J., Ouro, A., Ala-Ibanibo, L., Presa, N., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010040 · Cited by 134
Dissecting lipid metabolism alterations in SARS-CoV-2
Casari, I., Manfredi, M., Metharom, P., & Falasca, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101092 · Cited by 127
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
“One compared in liver and plasma a number of lipid species in order to discriminate control subjects from patients with steatosis, NASH, and cirrhosis [40].”
BackgroundThe Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines
Field, B. C., Gordillo, R., & Scherer, P. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.569250 · Cited by 117
Diet as an Exposure Source and Mediator of Per- and Polyfluoroalkyl Substance (PFAS) Toxicity
Roth, K., Imran, Z., Liu, W., & Petriello, M. C. (2020) · Frontiers in Toxicology · doi:10.3389/ftox.2020.601149 · Cited by 109
“Both dysregulated tyrosine metabolism and dysregulated glycerophospholipid metabolism have been previously associated with the severity of NAFLD progression (Gorden et al., 2015; Jin et al., 2016).”
BackgroundMetabolic signatures across the full spectrum of non-alcoholic fatty liver disease
McGlinchey, A. J., Govaere, O., Geng, D., Ratziu, V., Allison, M., Bousier, J., Petta, S., de Oliviera, C., Bugianesi, E., Schattenberg, J. M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100477 · Cited by 105
Yamamoto, Y., Sakurai, T., Chen, Z., Inoue, N., Chiba, H., & Hui, S. (2022) · Nutrients · doi:10.3390/nu14030579 · Cited by 104
“H patic lysoPE species were shown to be higher in patients with simple steatosis than in those wi normal st atosis [25,26], whereas hepatic lysoPE levels were lower in NASH than i simple steatosi [25].”
BackgroundLone, M. A., Santos, T. C. B., Alecu, I., Silva, L. C., & Hornemann, T. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.12.013 · Cited by 112
Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction
Alecu, I., Tedeschi, A., Behler, N., Wunderling, K., Lamberz, C., Lauterbach, M., Gaebler, A., Ernst, D., Veldhoven, P. P. V., Al‐Amoudi, A., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m068676 · Cited by 101
“and therefore may be of hepatic origin (22).”
BackgroundPlatelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
Ma, C., Fu, Q., Diggs, L. P., McVey, J. C., McCallen, J., Wabitsch, S., Ruf, B., Brown, Z. J., Heinrich, B., Zhang, Q., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.004 · Cited by 106
Lipidomics: Current state of the art in a fast moving field
O'Donnell, V. B., Ekroos, K., Liebisch, G., & Wakelam, M. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1466 · Cited by 97
“Plasma and urine lipids can be analyzed in a relatively noninvasive manner, enabling their measurement with precision medicine approaches that are now coming onstream (Gorden et al., 2015; Quehenberger et al., 2010; Quehenberger & Dennis, 2011).”
BackgroundInfluentialPathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 116
Zarrinpar, A., Gupta, S., Maurya, M. R., Subramaniam, S., & Loomba, R. (2016) · Gut · doi:10.1136/gutjnl-2015-309456 · Cited by 88
Self-citation1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma
Duan, J., & Merrill, A. H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.658823 · Cited by 95
“A recent double-blinded study of plasma, liver biopsies, and urinary lipids from 88 subjects with liver histology categorized as normal, steatotic, NASH, or cirrhotic (70) found that a diverse panel of 20 plasma lipids and aqueous metabolites separated these states by linear discriminant analysis, with the compounds t…”
BackgroundSelf-citationSphingolipid Metabolism and Signaling in Skeletal Muscle: From Physiology to Physiopathology
Tan, S., Guitton, J., Bourron, O., Stunff, H. L., & Hajduch, É. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00491 · Cited by 94
Sphingolipid metabolism in non-alcoholic fatty liver diseases
Régnier, M., Polizzi, A., Guillou, H., & Loiseau, N. (2018) · Biochimie · doi:10.1016/j.biochi.2018.07.021 · Cited by 94
Plasma lipidome reveals critical illness and recovery from human Ebola virus disease
Kyle, J. E., Burnum-Johnson, K., Wendler, J., Eisfeld, A. J., Halfmann, P., Watanabe, T., Sahr, F., Smith, R. D., Kawaoka, Y., Waters, K. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815356116 · Cited by 87
“Interestingly, PC(32:0), which could correspond to PC(16:0/16:0), was recently reported as a potential signature of progressive forms of fatty liver disease (6).”
BackgroundInfluentialRomeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
“Evidence supporting their benefits across a range of SMDs, including ASCVD, HFpEF, MASH, and CKD, is described in detail below.”
InfluentialNonalcoholic fatty liver disease stratification by liver lipidomics
Vvedenskaya, O., Rose, T. D., Knittelfelder, O. L., Palladini, A., Wodke, J. A. H., Schuhmann, K., Ackerman, J. M., Wang, Y., Has, C., Brosch, M., et al. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100104 · Cited by 89
“(13) covered 186 lipids in liver biopsies and plasma of 91 patients and revealed a combination of plasma biomarkers (including polyunsaturated glycero- and glycerophospholipids together with long-chain ceramides (Cer)) that distinguished NASH from NAFL.”
BackgroundResultInfluentialPeleman, C., Francque, S., & Berghe, T. V. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105088 · Cited by 99
Membrane lipids and transporter function
Stieger, B., Steiger, J., & Locher, K. P. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166079 · Cited by 88
Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus
Othman, A., Saely, C. H., Muendlein, A., Vonbank, A., Drexel, H., von Eckardstein, A., & Hornemann, T. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000073 · Cited by 85
Gaur, V., Connor, T., Sanigorski, A., Martin, S. D., Bruce, C. R., Henstridge, D. C., Bond, S. T., McEwen, K. A., Kerr-Bayles, L., Ashton, T. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.005 · Cited by 77
Martinou, E., Pericleous, M., Stefanova, I., Kaur, V., & Angelidi, A. M. (2022) · Diagnostics · doi:10.3390/diagnostics12020407 · Cited by 104
Babu, A. F., Csader, S., Männistö, V., Tauriainen, M., Pentikäinen, H., Savonen, K. P., Klåvus, A., Koistinen, V., Hanhineva, K., & Schwab, U. (2022) · Scientific Reports · doi:10.1038/s41598-022-10481-9 · Cited by 85
Insights into the role of hepatocyte PPARα activity in response to fasting
Régnier, M., Polizzi, A., Lippi, Y., Fouché, E., Michel, G., Lukowicz, C., Smati, S., Marrot, A., Lasserre, F., Naylies, C., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.035 · Cited by 72
Multi-omics profiling: the way toward precision medicine in metabolic diseases
Hu, C., & Jia, W. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab051 · Cited by 117
“In a double-blinded study of patients with different stages of NAFLD, a panel of 20 plasma metabolites such as glycerophospholipids, sphingolipids, sterols are associated with NAFLD progression based on the liver biopsy, which can be used to as potential differential biomarkers between NASH and steatosis (Gorden et al…”
BackgroundDual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
Hazlehurst, J. M., Oprescu, A. I., Nikolaou, N., Di Guida, R., Grinbergs, A. E. K., Davies, N. P., Flintham, R. B., Armstrong, M. J., Taylor, A. E., Hughes, B. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2928 · Cited by 71
Self-citationLipidSig: a web-based tool for lipidomic data analysis
Lin, W.-J., Shen, P.-C., Liu, H.-C., Cho, Y.-C., Hsu, M.-K., Lin, I.-C., Chen, F.-H., Yang, J.-C., Ma, W.-L., & Cheng, W.-C. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab419 · Cited by 68
“Similar methods have been used to interrogate causal effects of metabolites in nonalcoholic fatty liver disease (NAFLD) (43) and acute-on-chronic liver failure (ACLF) (44).”
MethodFatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
Yoo, W., Gjuka, D., Stevenson, H. L., Song, X., Shen, H., Yoo, S. Y., Wang, J., Fallon, M. B., Ioannou, G. N., Harrison, S. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189965 · Cited by 75
Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway
Alecu, I., Othman, A., Penno, A., Saied, E. M., Arenz, C., von Eckardstein, A., & Hornemann, T. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m072421 · Cited by 68
“Furthermore, 1-deoxySLs were found to be increased in patients with nonalcoholic steatohepatitis (14) and to interfere with the function and survival of pancreatic cells (15).”
BackgroundPresa, N., Clugston, R. D., Lingrell, S., Kelly, S. L., Merrill, A. H., Jana, S., Kassiri, Z., Gómez‐Muñoz, A., Vance, D. E., Jacobs, R. L., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.010 · Cited by 71
Self-citationMusso, G., Saba, F., Cassader, M., & Gambino, R. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101238 · Cited by 74
In vitro assessment of hepatotoxicity by metabolomics: a review
Cuykx, M., Rodrigues, R. M., Laukens, K., Vanhaecke, T., & Covaci, A. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2286-9 · Cited by 73
Wang, M., Ma, H., Guan, S., Luo, T., Zhao, C., Cai, G., Zheng, Y., Jia, X., Di, J., Li, R., et al. (2021) · Food & Function · doi:10.1039/d1fo01495a · Cited by 65
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques
Zhang, X., Ji, Y., Cheng, X., Cheng, Y., Yang, H., Wang, J., Zhao, L., Huang, Y., Sun, D., Xiang, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8116 · Cited by 61
Guerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 65
“…40:7), LysoPC (16:0, 16:1, 20:3, 22:5), PG (36:1, 36:2, 36:3, 38:3, 38:4); PI (32:1, 34:1, 36:4, 38:4, 40:4, 40:5) ↑ NASH CER d18:1/24:0, SM 42:3 ↓ NASH Gorden et al. (2015)115 31 CT BMI 40 kg/m2 17 NAFLD BMI 46 kg/m2 20 NASH BMI 47 kg/m2 20 Cirrhosis BMI 32 kg/m2 Liver biopsy Plasma TAG, CE, CER,…”
Hall, Z., Chu, Y., & Griffin, J. L. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b01097 · Cited by 59
Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus
Mwinyi, J., Boström, A. E. D., Fehrer, I., Othman, A., Waeber, G., Martí-Soler, H., Vollenweider, P., Marques-Vidal, P. M., Schiöth, H. B., von Eckardstein, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175776 · Cited by 58
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
“The activation of these genes triggers a cascade of events involving inflammatory processes, lipid metabolism regulation, and remodeling of the extracellular matrix [90].”
BackgroundSphingolipids Are Depleted in Alcohol-Related Liver Fibrosis
Thiele, M. S., Suvitaival, T., Trôst, K., Kim, M. G., de Zawadzki, A., Kjærgaard, M., Rasmussen, D. N., Lindvig, K. P., Israelsen, M. E., Detlefsen, S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.023 · Cited by 62
Lauterbach, M., Saavedra, V., Mangan, M., Penno, A., Thiele, C., Latz, E., & Kuerschner, L. (2020) · Autophagy · doi:10.1080/15548627.2020.1804677 · Cited by 58
Intestinal MYC modulates obesity-related metabolic dysfunction
Luo, Y., Yang, S., Wu, X., Takahashi, S., Sun, L., Cai, J., Krausz, K. W., Guo, X., Dias, H. B., Gavrilova, O., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00421-8 · Cited by 63
Rohrbach, T. D., Asgharpour, A., Maczis, M. A., Montefusco, D. J., Cowart, L. A., Bédossa, P., Sanyal, A. J., & Spiegel, S. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093799 · Cited by 57
Montandon, S. A., Somm, E., Loizides‐Mangold, U., Vito, C. D., Dibner, C., & Jornayvaz, F. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-53346-4 · Cited by 59
García‐Jaramillo, M., Spooner, M. H., Löhr, C. V., Wong, C. P., Zhang, W., & Jump, D. Β. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214387 · Cited by 64
Evolution of the liver biopsy and its future
Jain, D., Torres, R., Celli, R., Koelmel, J. P., Charkoftaki, G., & Vasiliou, V. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.04.01 · Cited by 59
“For example, lipidomics, the comprehensive measurement of lipids within a biological substrate or system, was able to distinguish NAFLD from NASH using specific glycerophospholipids, sphingolipids, and sterols (111).”
BackgroundTargeting Human Urinary Metabolome by LC–MS/MS: A Review
Rodríguez-Morató, J., Pozo, Ó. J., & Marcos, J. (2018) · Bioanalysis · doi:10.4155/bio-2017-0285 · Cited by 57
An intronic variant in the GCKR gene is associated with multiple lipids
Silva, L. F., Vangipurapu, J., Kuulasmaa, T., & Laakso, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46750-3 · Cited by 56
Caussy, C., Chuang, J.-C., Billin, A. N., Hu, T., Ya, W., Subramanian, G. M., Djedjos, C. S., Myers, R. P., Dennis, E. A., & Loomba, R. S. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820923904 · Cited by 59
“Hispanic or Latino, n (%) 84 (20) 43 (19) 41 (21) 0.”
Self-citationAzzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
“These findings confirm previous reports investigating circulating lipid species, suggesting that complex lipids enriched in DNL products could act as biomarkers of the disease [8,49,50].”
ResultFouqueray, P., Bolze, S., Dubourg, J., Hallakou‐Bozec, S., Theurey, P., Grouin, J., Chevalier, C., Dagorn, P. G., Moller, D. E., & Cusi, K. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100474 · Cited by 57
“These findings may be important given that elevated plasma levels of these classes are associated with NAFLD-NASH(50-52) and have been suggested to bepotential biomarkers of steatosis severity anddiseaseprogression.(50,53) Several of the DG and TG species affected by PXL770 (DG 32:2, DG 34:2, DG 36:1, DG 36:2, TG 50:4…”
BackgroundAdrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease
Nababan, S. H. H., Nishiumi, S., Kawano, Y., Kobayashi, T., Yoshida, M., & Azuma, T. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.04.009 · Cited by 53
Gu, J., Kong, A., Guo, C., Liu, J., Li, K., Ren, Z., Zhou, Y., Tang, M., & Shi, H. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114254 · Cited by 51
Liaw, L., Prudovsky, I. A., Koza, R. A., Anunciado-Koza, R. V. P., Siviski, M. E., Lindner, V., Friesel, R. E., Rosen, C. J., Baker, P. R. S., Simons, B. L., et al. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25522 · Cited by 50
Kayser, B. D., Lhomme, M., Prifti, E., Cunha, C. D., Marquet, F., Chain, F., Naas, I., Pelloux, V., Dao, M. C., Kontush, A., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201801897r · Cited by 61
Yu, X.-D., & Wang, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115157 · Cited by 56
Metadata
- Authors
- Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., Duan, J., Sullards, M. C., Leiker, T. J., Barkley, R. M., Quehenberger, O., Armando, A. M., Milne, S. B., Mathews, T. P., Armstrong, M. D., Li, C., Melvin, W. V., Clements, R. H., Washington, M. K., Mendonsa, A. M., Witztum, J. L., Guan, Z., Glass, C. K., Murphy, R. C., Dennis, E. A., Merrill, A. H., Russell, D. W., Subramaniam, S., & Brown, H. A.
- Affiliations
- Vanderbilt University Medical Center (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Georgia Institute of Technology (US)
- University of Colorado Denver (US)
- Duke Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Subramaniam, Shankar
- Brown, H.Alex
- ORCID
- Fahy, Eoin
- Maurya, Mano R.
- Gupta, Shakti
- Spann, Nathanael J.
- McDonald, Jeffrey G.
- Duan, Jingjing
- Barkley, Robert M.
- Quehenberger, Oswald
- Armando, Aaron M.
- Milne, Stephen B.
- Mathews, Thomas P.
- Washington, M.Kay
- Witztum, Joseph L.
- Guan, Ziqiang
- Glass, Christopher K.
- Murphy, Robert C.
- Dennis, Edward A.
- Merrill, Alfred H.
- Russell, David W.
- Subramaniam, Shankar
- Brown, H.Alex
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 56
- Issue
- 3
- Pages
- 722-736
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4340319
- OpenAlex
- W2134541386
- Cited by
- 372
- References
- 73
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 38 · 2023: 34 · 2022: 34 · 2021: 56 · 2020: 42 · 2019: 32 · 2018: 25 · 2017: 20 · 2016: 21 · 2015: 11
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2040 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL106579)
- National Institute of Mental Health (T32MH093366)
- National Institute of General Medical Sciences (U54GM069338, R24GM107784, GM U54 069338)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK074868, P30DK058404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatosis, disease progression, lipidomics, plasma metabolites, biomarkers, glycerophospholipids, sphingolipids, sterols, liver biopsy, diagnostic signature, NAFLD staging
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Biomarkers, Polymorphism, Single Nucleotide, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.